This Week In Blood: January 10, 2013

Source : American Society of Hematology

Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, and Deputy Editor Nancy Berliner, MD.

Systemic delivery of a TLR7 agonist in combination with radiation primes durable anti-tumor immune responses in mouse models of lymphoma, Dovedi et al.

This week’s plenary paper offers a promising potential new immunotherapeutic modality for the treatment of lymphoma. The authors present convincing data to suggest that a toll-like receptor 7 (TLR7) agonist sensitizes tumor cells to radiotherapy. In a mouse model, this increases radiation-induced cell death and prolongs responses.

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia, Horn et al.

The success of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia (CML) has led to early investigation of the safety of discontinuing therapy for patients with prolonged deep response to treatment. In this manuscript, Horn and colleagues present a way of predicting the safety of therapy discontinuation.

Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms, Cazzola et al.

This manuscript, featured as this week’s Perspective, discusses how our understanding of the pathophysiology of myelodysplastic syndromes (MDS) and other hematologic malignancies has been transformed over the last year with the discovery of the prevalence and prognostic significance of mutations in genes encoding the cellular splicing machinery.

Reporters who wish to receive a copy of any of the manuscripts highlighted above or would like to request an interview with the authors may contact Andrea Slesinski at 202-552-4927 or  aslesinski@hematology.org.  


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.
 

blood® is a registered trademark of the American Society of Hematology.
 

  • <<
  • >>

Articles List

  • Characterizing the Microbiome

    Characterizing the Microbiome

    The microbiome is the community of all the microorganisms in a location. Microbiomics, in turn, is the study of that community and its ecosystem. Microbiomists use high-throughput sequencing, mass spectrometry, biochemical analysis and other tools to figure out which organisms are present, how many of each there are, what genes they carry, what RNAs they express, what proteins they make and what metabolites they generate. Often, the goal is to gain a better understanding of the relationships among community members so as ultimately to be able to manipulate them.
  • Therapeutic Antibodies

    Therapeutic Antibodies

    In the pharmaceuticals industry, antibodies are big business. Pharmaceuticals companies are keen to build on that success, and their development pipelines are full of new antibodies. But many of these aren’t your garden-variety IgGs. Modern antibody therapeutics are more sophisticated than ever.

Disqus Comments